These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 9346845

  • 1. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB, Glasier LM, Ellert NW, Cachia P, Kohn W, Lee KK, Paranchych W, Hodges RS, Irvin RT.
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
    [Abstract] [Full Text] [Related]

  • 2. Pilin-based anti-Pseudomonas vaccines: latest developments and perspectives.
    Hahn H, Lane-Bell PM, Glasier LM, Nomellini JF, Bingle WH, Paranchych W, Smit J.
    Behring Inst Mitt; 1997 Feb; (98):315-25. PubMed ID: 9382755
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synthetic peptide vaccine development: measurement of polyclonal antibody affinity and cross-reactivity using a new peptide capture and release system for surface plasmon resonance spectroscopy.
    Cachia PJ, Kao DJ, Hodges RS.
    J Mol Recognit; 2004 Feb; 17(6):540-57. PubMed ID: 15386623
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Solution secondary structure of a bacterially expressed peptide from the receptor binding domain of Pseudomonas aeruginosa pili strain PAK: A heteronuclear multidimensional NMR study.
    Campbell AP, Bautista DL, Tripet B, Wong WY, Irvin RT, Hodges RS, Sykes BD.
    Biochemistry; 1997 Oct 21; 36(42):12791-801. PubMed ID: 9335536
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ, Gerçeker AA, Koles NL, Pollack M, Pier GB.
    Invest Ophthalmol Vis Sci; 1997 Jun 21; 38(7):1418-25. PubMed ID: 9191605
    [Abstract] [Full Text] [Related]

  • 10. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K, Wiener-Kronish JP, Sawa T.
    Microbiol Immunol; 2009 Nov 21; 53(11):587-94. PubMed ID: 19903258
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of pilus-mediated adhesion of Pseudomonas aeruginosa to human buccal epithelial cells by monoclonal antibodies directed against pili.
    Doig P, Sastry PA, Hodges RS, Lee KK, Paranchych W, Irvin RT.
    Infect Immun; 1990 Jan 21; 58(1):124-30. PubMed ID: 1967166
    [Abstract] [Full Text] [Related]

  • 12. Crystal structure of Pseudomonas aeruginosa PAK pilin suggests a main-chain-dominated mode of receptor binding.
    Hazes B, Sastry PA, Hayakawa K, Read RJ, Irvin RT.
    J Mol Biol; 2000 Jun 16; 299(4):1005-17. PubMed ID: 10843854
    [Abstract] [Full Text] [Related]

  • 13. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
    Cachia PJ, Hodges RS.
    Biopolymers; 2003 Jun 16; 71(2):141-68. PubMed ID: 12767116
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa.
    Gilleland HE, Gilleland LB, Staczek J, Harty RN, Garcia-Sastre A, Engelhardt OG, Palese P.
    Behring Inst Mitt; 1997 Feb 16; (98):291-301. PubMed ID: 9382753
    [Abstract] [Full Text] [Related]

  • 16. Adherence of Pseudomonas aeruginosa and Candida albicans to glycosphingolipid (Asialo-GM1) receptors is achieved by a conserved receptor-binding domain present on their adhesins.
    Yu L, Lee KK, Hodges RS, Paranchych W, Irvin RT.
    Infect Immun; 1994 Dec 16; 62(12):5213-9. PubMed ID: 7525482
    [Abstract] [Full Text] [Related]

  • 17. Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections.
    Palaszynski S, Pinkner J, Leath S, Barren P, Auguste CG, Burlein J, Hultgren S, Langermann S.
    Dev Biol Stand; 1998 Dec 16; 92():117-22. PubMed ID: 9554264
    [Abstract] [Full Text] [Related]

  • 18. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU, Domdey H, Schödel F, Blum B, Lücking C, Knapp B, Muth G, Hungerer KD, Bröker M.
    Behring Inst Mitt; 1994 Dec 16; (95):85-96. PubMed ID: 7538752
    [Abstract] [Full Text] [Related]

  • 19. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice.
    Ohama M, Hiramatsu K, Miyajima Y, Kishi K, Nasu M, Kadota J.
    FEMS Immunol Med Microbiol; 2006 Jun 16; 47(1):107-15. PubMed ID: 16706793
    [Abstract] [Full Text] [Related]

  • 20. Immunological studies of the disulfide bridge region of Pseudomonas aeruginosa PAK and PAO pilins, using anti-PAK pilus and antipeptide antibodies.
    Lee KK, Sastry PA, Paranchych W, Hodges RS.
    Infect Immun; 1989 Feb 16; 57(2):520-6. PubMed ID: 2563257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.